William Meyers
Contributor since: 2011
Latest Articles
Mylan Grinding Towards Greatness
Incyte Should Break Out Of Doldrums
Epizyme Should Pop When Tazemetostat Hold Clears
Alnylam: Fully Priced, But A Future Star
Microchip A Buy On Pullback, Future Growth Potential
Alexion: Priced Right For Long-Term Investors
Regeneron: A Buy On Dupixent And Pipeline
Buy Biogen For Alzheimer's Therapy Pipeline
Agenus Illustrates Dilution And Non-Dilution Perils
Vertex Pharmaceuticals: Opportunities And Dangers
Inovio: Time To Think About 2020
Gilead Q2 Results Could Initiate A Rally
Star Bulk Undervalued On Rates, Oaktree Stock Sale
Corvus Pharmaceuticals Remains A High-Risk Investment
Amgen Should Rebound On Aimovig And Kyprolis Revenue
Celldex Therapeutics Salvage Value
GlaxoSmithKline Combines Dividend With Growth Potential
Immunomedics: Short-Term Risk, Long-Term Opportunity
Acceleron: Luspatercept New Data Is A Buy Signal
5 Reasons Why Celgene Will Recover
Athenex: Wait To See New Drug Pricing
Achaogen: Buy Before The June 25 PDUFA Date
Tetraphase Pharmaceuticals, My Favorite 2H 2018 Biotech
Regeneron Unknown: Eylea Future Competition Effects
Seattle Genetics Fairly Valued, Pending Data
Biogen Buy Signal: Alzheimer's Royalties Option
Xilinx's ACAP Could Be A Computing Game-Changer
Biogen's Ionis Deal Is Brilliant
Merrimack Pharmaceuticals Potential Catalyst A Likely Bust
Akcea Undervalued As Commercial Launches Near
GlycoMimetics: Buy This Dip
Tocagen Drug Candidate Looks Undervalued, But Very Risky